At Festival of Genomics London: Genomics plc
Genomics plc was founded in 2014 by four leading Oxford academics, including Professor Peter Donnelly, Director of The Wellcome Trust Centre for Human Genetics, and Professor Gil McVean, Director of The Big Data Institute. The Company has developed a unique platform for genomic data analysis and interpretation that combines world-leading expertise in statistical analysis and data mining with a unique integrated database linking genotypes and phenotypes.
The past year been a particularly exciting time for the Company, with achievements that include:
- An agreement with Vertex Pharmaceuticals ─ marking the fourth such pharma partnership ─ that enables more informed drug research and development by using Genomics plc’s integrated database and state-of-the-art analysis tools. Other partners are MSD/Merck, Biogen and Eisai.
- A collaboration agreement with Oxford University and the Oxford University Hospitals NHS Trust in a research project focused on the translation of whole genome sequencing into clinical practice.
- Further development of Genomics plc’s novel clinical software tools, with beta testing initiated with high-volume NGS users in the UK and US.
- A preview of Genomics plc’s integrated platform on genetic association, allowing delegates at the American Society of Human Genetics (ASHG) 2015 conference to access part of its database via a mobile app,
- The appointment of the 40th member of Genomics plc’s team, which primarily comprises statistical geneticists, bioinformaticians and software developers.
- The appointment of Sek Kathiresan, M.D., one of the world leaders in the genetics of heart disease, to be Chair of the Company’s newly-formed Scientific Advisory Board.
Genomics England, the company running the UK project to sequence 100,000 genomes, has also appointed Genomics plc as a Platform Provider and awarded the Company three SBRI grants.
At the Festival of Genomics Lonon this month, the company is highlighting the capabilities of the platform it is developing, which will be a powerful tool to help learn about human biology in humans and de-risk the drug development process. Co-founder Dr. Chris Spencer will be showing some examples at 12.00 – 12.30 in the Enabling Data stream.
Genomics plc can be contacted using email@example.com